The synergy of this combination has been largely attributed to tumor-intrinsic immunomodulatory activity of CDK4/6 inhibitors; for example through altering MHC I and PD-L1 expression and increasing tumor cell production of T cell chemoattractants9,11,13,15. Here, CDK4 is linked to neoplasm.